PTC Therapeutics
Roche’s Evrysdi drug for SMA shown to significantly increase survival
April 15, 2021PTC Therapeutics, Roche, pharma, pharma news, spinal muscular atrophy
Roche’s Evrysdi therapy for the treatment of children with type 1 spinal muscular atrophy (SMA) has been shown to increase …
Roche’s SMA treatment Evrysdi approved by European Commission
March 30, 2021Manufacturing and Production EMA, European Commission, PTC Therapeutics, Roche, sma, spinal muscular atrophy
The European Commission has granted marketing authorisation to Roche and PTC Therapeutics’ Evrysdi, for the treatment of patients aged 2 …
Roche and PTC’s SMA treatment shows positive trial results
March 16, 2021Manufacturing and Production PTC, PTC Therapeutics, Roche, sma, spinal muscular atrophy
Roche and PTC Therapeutics’s Evrysdi treatment for children and adults with Type 2 or Type 3 spinal muscular atrophy (SMA) …
PTC Therapeutics’ results in SMA has Biogen nervous
June 19, 2018Manufacturing and Production, Research and Development Biogen, PTC Therapeutics, biotech, drugs, pharma, pharmaceutical
Biogen currently has the only product on the market approved to treat spinal muscular atrophy (SMA), in Spinraza, and that …
Duchenne drug poised to cost $35,000 but with major catch
May 9, 2017Manufacturing and Production, Sales and Marketing Duchenne Muscular Dystrophy, PTC Therapeutics, marathon
For those that have not followed the story, Emflaza was successfully taken through the FDA regulatory process by Marathon as …
NICE recommends PTC Therapeutics Duchenne muscular dystrophy treatment
July 20, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, PTC Therapeutics
PTC Therapeutics has announced that the National Institute for Health and Care Excellence has issued final guidance recommending Translarna (ataluren) …
Nice extends price-negotiation talks for PTC’ muscle wasting drug
May 4, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, market access, regulation
UK regulators have extended the cost negotiation talks with PTC Therapeutics (Nasdaq: PTCT) by a week for the drug to …
NICE recommends PTC Therapeutics’ Translarna to treat Duchenne muscular dystrophy
April 18, 2016Sales and Marketing DMD, Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, regulation
Shares in drug maker PTC Therapeutics (Nasdaq: PTCT) jumped after the National Institute for Health and Care Excellence (NICE) backed …
PTC Therapeutics to cut jobs after FDA rejects Duchenne drug
March 24, 2016Manufacturing and Production Duchenne Muscular Dystrophy, PTC Therapeutics
PTC Therapeutics has announced plans to reduce its operating expenses that will see it cut almost a fifth of its …
PTC Therapeutics to file new Phase III data for genetic muscle disorder drug in Canada
March 15, 2016Manufacturing and Production, Research and Development Canada, PTC Therapeutics, Translarna, nonsense mutation Duchenne muscular dystrophy, phase III
PTC Therapeutics (Nasdaq: PTCT) said it does not expect the Canadian regulators to review its trial drug to treat a …
PTC Therapeutics makes series of changes
January 27, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing PTC Therapeutics
Biopharma firm PTC Therapeutics has expanded its senior management team with a raft of appointments. Robert Spiegel (pictured) becomes its …
Roche inks $490 million deal with PTC Therapeutics
November 30, 2011Research and Development, Sales and Marketing PTC Therapeutics, Roche
Roche has signed a $490 million deal with specialist biotech firm PTC Therapeutics. Roche is paying PTC $30 million upfront …
AstraZeneca signs cancer drug discovery collaboration
June 30, 2011Research and Development AstraZeneca, PTC Therapeutics
AstraZeneca has signed a deal with PTC Therapeutics to use the company’s proprietary drug discovery platform to discover new cancer …
